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Abstract 22 
23 
 Strongyloidiasis is widely distributed in the tropical and subtropical areas. 24 
Ivermectin is the drug of choice for the treatment. However, The concerns about relying 25 
treatment on a single drug make identification of new molecules a priority. 26 
Alkylphospholipid analogues, including edelfosine, are a group of synthetic compounds 27 
that have shown activity against protozoan parasites and also against the helminth 28 
parasite Schistosoma mansoni. The activity of edelfosine, miltefosine, perifosine against 29 
Strongyloides venezuelensis was assessed both in cultures of third-stage larvae (L3) and 30 
infected mice. The induction of an apoptosis-like mechanism in larvae after treatment 31 
was studied. Larval motility and XTT (2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-32 
tetrazolium-5-carboxanilide) assay were used to evaluate antiparasitic drug efficacy in 33 
L3 cultures as screening test. Edelfosine displayed the highest activity against L3 and the 34 
best selectivity index (LD50 = 49.6 ± 5.4 µM, SI = 1.1) compared to miltefosine or 35 
perifosine activity. L3 after culture with edelfosine were not able to develop an 36 
infection in CD1 mice. The oral treatment with edelfosine showed reduction of 47% in 37 
parasitic females allocated in the gut. Moreover, DNA fragmentation was also 38 
observed by TUNEL staining in edelfosine treated L3. These data suggest that 39 
edelfosine could be an effective drug against strongyloidiasis, probably through 40 
apoptosis-like cell death.41 
42 
1. Introduction43 
 Strongyloidiasis is caused by nematodes of the genus Strongyloides widely 44 
distributed in tropical and subtropical areas. There are about 52 species in the genus, 45 
but only S. stercoralis and S. fuelleborni infect humans. It is estimated that 30 to 100 46 
million people are infected worldwide (Bisoffi et al. 2013, Puthiyakunnon et al. 2014). 47 
Infective third-stage larvae (L3) penetrate the skin, migrate to the lungs, reaching the 48 
trachea, oesophagus and small intestine where became mature. Parthenogenetic females 49 
lay eggs that hatch into rhabditiform larvae (L1), which are eliminated in the faeces. 50 
Some L1 remain and molt into L3 establishing reinfection cycles. The clinical 51 
strongyloidiasis ranges from asymptomatic infection, cutaneous larva migrans, Löeffler 52 
syndrome, chronic intestinal infection to life-threatening disseminated hyperinfection 53 
depending upon the immune status of the patient and the presence of risk factors, 54 
such as corticosteroid therapy, stem-cell transplantation, alcoholism or HTLV-1 55 
infection. Disseminated hyperinfection involves a massive spread of the parasite in 56 
situations of immunosuppression with high mortality (Montes et al. 2010, Schar et al. 57 
2013, Sharifdini et al. 2014). 58 
 Thiabendazole was long the drug of choice for treating strongyloidiasis. 59 
However, it is no longer available due to the strong adverse side effects. Albendazole, 60 
another broad- spectrum drug and anthelminthic agent is effective against S. stercoralis. 61 
Currently, ivermectin is the best therapeutic option for the treatment of strongyloidiasis, 62 
with cure rates from 70% to 85% of chronically infected patients (Pitisuttithum et al. 63 
1995, Igual-Adell et al. 2004, Stuart et al. 2009). The anti-Strongyloides activity of 64 
ivermectin is superior to that of albendazole (Suputtamongkol et al. 2011). 65 
Alkylphospholipid (APL) analogues include edelfosine, miltefosine and perifosine, a 66 
heterogeneous group of natural lipids (Fig. 1) with promising anticancer activity. These 67 
compounds act at the level of cell membranes affecting apoptotic signalling. Edelfosine 68 
(1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine) is considered the prototype 69 
APL molecule and a promising antitumor ether phospholipid drug that acts by activating 70 
apoptosis through its interaction with cell membranes (Gajate and Mollinedo 2002, 71 
Mollinedo et al. 2004, Gajate and Mollinedo 2007). In addition to its antitumor activity, 72 
edelfosine exerts cytotoxic activity against parasitic protozoa such as Leishmania spp 73 
(Varela et al. 2012), Trypanosoma cruzi (Luna et al. 2009), Trichomonas vaginalis 74 
(Rocha et al. 2014), Giardia lamblia (Eissa and Amer 2012), Acanthamoeba keratitis 75 
(Polat et al. 2012), Neospora caninum (Debache and Hemphill 2012), Babesia spp and 76 
Theileria equi (AbouLaila et al. 2014). These compounds are also active against larval 77 
stages and eggs of the free-living nematode Caenorhabditis elegans (Sanchez-Blanco et 78 
al. 2014) and the blood fluke Schistosoma mansoni (Eissa et al. 2011, Bertao et al. 79 
2012, Yepes et al. 2014). The human parasite S. stercoralis cannot complete its 80 
development in immunocompetent mice and rats. Thus, attention has been focused on 81 
the related parasites Strongyloides ratti and Strongyloides venezuelensis, parasite of 82 
rats, to study host-parasite relationships (Sato and Toma 1990), and as general 83 
experimental models of intestinal parasitism (Yasuda et al. 2014). 84 
In the present study, the efficacy of alkylphospholipid derivatives in killing 85 
S. venezuelensis was investigated using in vitro and in vivo approaches, comparing it 86 
to other APLs and assessing its potential as a chemotherapeutic alternative for the 87 
treatment of strongyloidiasis. Insights into the mode of action of edelfosine in killing 88 
S. venezuelensis larvae were also investigated using an in vitro approach.89 
90 
2 Materials and Methods91 
2.1. Ethics statement 92 
 The animal procedures in this study complied with the Spanish (L 6/3013, RD 93 
53/2013) and European Union (Di 2010/63/CE) regulations regarding animal 94 
experimentation for the protection and humane use of laboratory animals. The 95 
University of Salamanca’s accredited Animal Experimentation Facilities (Registration 96 
number PAE/SA/001) were used for these procedures. The University of Salamanca’s 97 
Ethics Committee also approved the procedures that were used in this study (Permit 98 
Number: 8402). The animals’ health and welfare status was monitored throughout the 99 
experiments by a health surveillance program according to Federation of European 100 
Laboratory Animal Science Associations (FELASA) guidelines and also by the 101 
University of Salamanca’s standardized protocols. All efforts were made to minimize 102 
suffering. 103 
104 
2.2. Animals105 
Sixty-nine six-week-old CD1 mice weighing 25-30 g and twelve male Wistar 106 
rats weighing 150-200 g (Charles River Laboratories, Barcelona, Spain) were used 107 
for in vivo experiments and life cycle maintenance, respectively. Animals were 108 
maintained in the University of Salamanca’s Animal Care Facilities and kept in standard 109 
polycarbonate and wire cages with food and water ad libitum with regular 12 h light– 110 
dark periods and 20-22°C temperature. Animals at the end of the experimentation or 111 
those presenting any deterioration of the health status were humanely euthanized by 112 
intraperitoneal injection of a lethal dose of pentobarbital (100 mg/kg). Size of groups 113 
was calculated by power analysis (Charan and Kantharia 2013) using the “size.fdr” 114 
package for R and following the 3Rs recommendations (Festing and Altman 2002). 115 
116 
2.3. Drugs117 
Edelfosine (1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocoline) was 118 
obtained from R. Berchtold (Biochemisches Labor, Bern, Switzerland). Miltefosine 119 
(hexadecylphosphocholine) was from Calbiochem (Cambridge, MA). Perifosine 120 
(octadecyl-(1,1-dimethyl-piperidinio-4-yl)-phosphate) was from Zentaris (Frankfurt, 121 
Germany). Stock sterile solutions of the distinct APLs (2 mM) were prepared in RPMI-122 
1640 culture medium (Invitrogen, Carlsbad, CA), supplemented with 10% heat- 123 
inactivated fetal bovine serum (FBS), 2 mM glutamine, 100 IU/mL penicillin, and 124 
100 µg/mL streptomycin, as previously described (Mollinedo et al. 1997). Ivermectin 125 
was purchased from Sigma Aldrich and diluted in dimethyl sulfoxide (DMSO) at a final 126 
concentration of 10 µM. 127 
128 
2.4. S. venezuelensis life cycle maintenance and parasitological techniques 129 
The S. venezuelensis strain from Department of Parasitology, Federal University 130 
of Minas Gérais (Brazil) was maintained by serial passage in Wistar rats at the 131 
University of Salamanca’s animal care facilities since 2003, according to the procedure 132 
described by Martins et al. (Martins et al., 2000). Briefly, rats were subcutaneously 133 
infected with 6000 third stage larvae (L3) in 500 µL of phosphate buffered saline (PBS) 134 
using a 23-gauge needle syringe. Faeces from infected rats (5-14 days p.i) were cultured 135 
with vermiculite and water at 28ºC for 3-4 days and then L3 were recovered using a 136 
Baermann apparatus. Larvae were decontaminated by mild sodium hypochlorite 137 
treatment and exposure to an antibiotic and antifungal cocktail according to Martins et 138 
al. (2000). Absence of bacteria was confirmed by culturing L3 on a Petri plate 139 
containing blood- agar at 28 ºC during 24 h. Faecal egg counts were performed by 140 
placing animals individually on grids over clean, moist absorbent paper and allowing 141 
them to defecate. Individual faecal samples were collected, preserved in a 10% formalin 142 
buffered solution and eggs were counted in triplicate samples using the McMaster 143 
technique. The upper halves of the small intestines of experimental rats were removed 144 
at necropsy, cut longitudinally, minced and placed in a sedimentation cup wrapped by 8 145 
layers of gauze in phosphate buffered saline for two hours at 37 °C. Parasitic females 146 
were collected from the sediment and counted. 147 
148 
2.5. Cytotoxicity in murine macrophages 149 
For cytotoxicity assays the mouse-derived peritoneal macrophage cell line 150 
J774.2 (Sigma-Aldrich) was used. Cells were maintained at 37 °C with a 5% CO2 151 
atmosphere and cultured in plastic culture flasks with Dulbecco's Modified Eagle 152 
Medium (DMEM) supplemented with 10% heat inactivated fetal calf serum (Sigma-153 
Aldrich), 2 mM glutamine (Sigma-Aldrich), 100 U/mL penicillin (Sigma-Aldrich) and 154 
100 μg/mL streptomycin (Sigma-Aldrich). 200 μL of a suspension containing 2 x 105 155 
macrophages/mL were added onto 96 well flat-bottom microplates (NUNC) and 156 
allowed to incubate for 2 h. After, APL’s were added at different concentrations 157 
ranging from 1 to 100 µM for the next 48 h and 50 µL of XTT were added to each well 158 
and incubated again for 24 h at 37 ºC, 5% CO2. Finally, 100 µL of DMSO 159 
(Sigma-Aldrich) were added to each well and the absorbance was measured at 492 nm 160 
using an ELISA-plate reader (Anthos 2010; Anthos Labtec Instruments, Wals, Austria). 161 
Ivermectin-treated, untreated and DMSO-treated macrophages were used as controls. 162 
Each concentration was assayed in triplicate in three independent experiments and the 163 
IC50 value for each APL was calculated by sigmoidal regression analysis (Gomez-Ayala 164 
et al. 2010). 165 
166 
2.6. In vitro activity of alkylphospholipids 167 
A batch of 7000 S. venezuelensis L3 were rinsed twice with PBS and 100 168 
larvae per well were distributed in 24-well flat bottom culture plates. Larvae were 169 
incubated at 28 ºC for 2 h to allow adaptation, and treated with edelfosine, miltefosine 170 
or perifosine in the range of 1 to 100 µM for 72 h as screening test (Keiser et al. 171 
2008, Tritten et al. 2011, Olounlade et al. 2012). Mortality was assessed as the lack of 172 
any movement detected during 2 min of observation under the microscope 173 
(magnification 4x), at 24, 48 and 72 h after treatment. Video recordings were taken 174 
using an AM423 camera and DinoCapture software version 2.0, (Dino-Lite Digital 175 
microscope, Naarden, Holland). Larvae were considered dead when no movement was 176 
detected for at least two minutes of detailed examination. As controls, S. venezuelensis 177 
larvae were incubated in the presence of PBS or treated with ivermectin 10 µM. All 178 
experiments were carried out in triplicate and performed at three different times. The 179 
colorimetric XTT assay was also used for measuring larvae viability (Paull et al. 1988). 180 
After treatment, S. venezuelensis L3 were incubated with 50 µL of XTT for 24 h and 181 
the absorbance was measured at 492 nm using an ELISA-plates reader (Anthos 2010; 182 
Anthos Labtec Instruments, Wals, Austria). Untreated, heat-killed and ivermectin-183 
treated S. venezuelensis L3 were used as controls. The antiparasitic activity of the 184 
compounds was expressed as the concentration able to kill 50 % of larvae (LD50) and it 185 
was calculated by sigmoidal regression analysis (Gomez-Ayala et al. 2010). The 186 
Selectivity Index (SI = mammalian cell IC50/ Larva LD50) for each compound was 187 
calculated to compare the strongyloidicidal activity with its respective mammalian cell 188 
cytotoxicity. 189 
190 
2.7. Viability of edelfosine-treated-L3 in mice 191 
S. venezuelensis L3 were rinsed twice with PBS and 100 larvae were 192 
distributed per well in 24-well flat bottom culture plates. Larvae were incubated 193 
with 5, 10, 20 and 40 µM of edelfosine for 24 h at 28 ºC. Untreated-L3 and 194 
ivermectin-treated-L3 were used as controls. After incubation period larvae were 195 
carefully recovered, re-suspended in PBS and used to subcutaneously infect thirty-six 196 
CD1 mice randomly distributed in six groups with six animals each. Parasite eggs in 197 
faeces were monitored on days 5, 6 and 7 p.i to assess the ability of edelfosine-treated-198 
L3 to infect mice. 199 
200 
2.8. Edelfosine activity against S. venezuelensis infection in mice201 
Two different experiments were performed to assess the in vivo activity of 202 
edelfosine. In the first experiment, mice were randomly distributed in three experimental 203 
groups with 5 mice per group as follows: Infected control; Infected and treated with 204 
ivermectin; Infected and treated with edelfosine. Ivermectin was administered orally at 205 
0.2 mg/kg/day once on day 5 p.i. and edelfosine was administered at 20 mg/kg/day 206 
from the day of the infection to day 5 p.i. since migrant larvae and adults are present in 207 
human strongyloidiasis. All animals were infected by subcutaneous injection with 208 
3000 L3 of S. venezuelensis resuspended in PBS. Edelfosine was administered to 209 
reach the therapeutical concentration synchronically with ivermectin after day 5 p.i 210 
following previous studies (Yepes et al. 2014). Parasitic females were recovered from 211 
the gut and eggs in faeces were counted on day 7 p.i using groups of five animals. In 212 
the second experiment, mice were randomly distributed in three experimental groups 213 
with six mice per group with the same groups as above and we conducted faecal egg 214 
counts on days 5, 7, 9, 11, 15, 17 and 19 p.i.  215 
2.9. Assessment of apoptosis-like cell death by TUNEL assay 216 
217 
DNA fragmentation, which usually occurring in apoptosis-like cell death was 218 
analysed by the TUNEL (terminal deoxynucleotidyl transferase dUTP nick-end 219 
labeling) technique as previously described (Gajate et al. 2009). Larvae were washed 220 
with PBS, centrifuged at 1500 rpm for 3 min, mounted on poly-L-lysine-coated 221 
microscope slides (Menzel-Gläser, Braunschweig, Germany) and incubated for 24 h at 222 
37 ºC to stick the L3 to the slides. Larvae were then fixed in 4% paraformaldehyde 223 
(Sigma, St. Louis, MO) for 25 min, and washed with PBS as above. Fixed parasites 224 
were treated with trypsin and 0.25% EDTA, and stained for fragmented DNA using the 225 
Fluorescein Apoptosis Detection System (Promega, Madison, WI) according to the 226 
manufacturer's instructions. Propidium iodide was added for 15 min to stain nuclei of 227 
both apoptotic and non-apoptotic cells in red, whereas fluorescein-12-dUTP was 228 
incorporated at the 3′- OH ends of fragmented DNA resulting in localized green 229 
fluorescence within the nuclei of apoptotic cells. Samples were analysed with a Zeiss 230 
LSM 510 laser scan confocal microscope. 231 
232 
2.10. Statistical analysis233 
Data are expressed as mean and standard deviation (SD). Test for normality was 234 
performed by Kolmogorov-Smirnov and homogeneity of variance was tested by the 235 
Barrett test. Then one-way ANOVA analysis of variance, followed by Tukey’s honest 236 
significance (HDS) test was performed to determine any statistical differences between 237 
treated and untreated controls. Differences were considered statistically significant at p 238 
<0.05. The data were processed using GraphPad Prism 5 (GraphPad Software, San 239 
Diego, CA) for Mac. 240 
3. Results 241 
3.1. Experimental infection and treatments 242 
All mice used in this study (69/69) remained alive during the whole time-course 243 
experiments. According to our health surveillance program the status health of all 244 
animals used here was optimal during the experimentation. Any symptoms of severe 245 
pain, excessive distress, suffering or an impending death were observed in any of the 246 
animals. The success of the experimental infection was verified in each mouse by the 247 
observation of larvae released in the faeces, demonstrating that all animals were 248 
infected. Daily oral administration of 20 mg/kg edelfosine and 10 mg/kg ivermectin 249 
were well tolerated by CD1 mice in all experiments. 250 
251 
3.2. Cytotoxicity in murine macrophages 252 
 Cytotoxicity of each compound was evaluated the in macrophage cell line by 253 
calculating the IC50 for each APL, at six different concentrations. APL cytotoxicity 254 
was ranked as follow: edelfosine (IC50 53.4 ± 5.3 µM) < perifosine (IC50 52.8±6.3 µM) 255 
< miltefosine (IC50 27.3 ± 3.8 µM), thus showing that edelfosine is the less toxic 256 
compound to the macrophages (Table 1). 257 
258 
3.3. In vitro activity of APLs against S. venezuelensis third stage larvae 259 
First, in vitro the anti-Strongyloides activity of edelfosine, miltefosine and 260 
perifosine were analysed through XTT assay after 72 h of incubation using L3 261 
cultures with a range of 1-100 µM. Edelfosine showed the highest efficacy in killing 262 
the parasite, being effective at ≥ 40 µM with a LD50 value of 49.6±5.3 µM evaluated 263 
by the XTT assay (Fig. 2). It would be necessary to administer edelfosine 80 or 100 264 
µM to attain efficacy similar activity to that of ivermectin, the drug of choice for 265 
treating strongyloidiasis (LC50 = 0.41 ± 0.12 µM). Miltefosine and perifosine also 266 
showed efficacy in killing the parasite at higher concentrations, but their anti-267 
Strongyloides activity seems rather poor as compared to either edelfosine or ivermectin 268 
(LD50 = 85.7 ± 8.7 µM and LD50 = 90.6 ± 10.5 µM, respectively; Fig. 2). Edelfosine 269 
also showed the highest Selectivity Index as demonstrated by the SI value, ranked as 270 
follows: edelfosine (SI 1.1) > perifosine (SI 0.6) > miltefosine (SI, 0.6).271 
272 
3.4. Dose- and time-dependent effects of APLs on S. venezuelensis larvae273 
How the dose and the time of action of APL derivatives affected the parasites were 274 
investigated and microscopic observation of larvae incubated was performed at 24, 48 275 
and 72 h to determine decrease in motor activity. As shown in S1-S3 videos, 276 
edelfosine’s activity is time and dose-dependent, reaching its maximum efficacy at 72 h 277 
showing mortality of S. venezuelensis L3 equal to 92% at 80 µM and 100% at 100 µM. 278 
These results were similar to those obtained with ivermectin at 10 µM. At 48 h 279 
significant efficacy of edelfosine (about 50%) was also found with 80 and 100 µM280 
(videos S1-S3). Miltefosine’s activity was also time and dose dependent and it was 281 
inferior to that of edelfosine, showing its maximum activity at 100 µM being close to 282 
54% of reduction in larvae motility (videos S4-S6). Perifosine was the ALP with the 283 
lowest activity against larvae. Only at higher concentrations (≥ 80 µM) and after 72h of 284 
treatment perifosine reached a significant reduction of larvae motility (66%) (videos 285 
S7-S9). Untreated S. venezuelensis larvae remained alive during the next 72h after 286 
being cultured, reaching a motility of around 92%, whilst ivermectin-treated larvae were 287 
completely killed at 10 µM after 24h of treatment.288 
289 
3.5. Edelfosine treated-L3 are not able to infect mice. 290 
In order to complete the assessment of the lethal effect of edelfosine L3 cultures 291 
were treated with increasing concentrations of the drug, and after 24 hours they were292 
used to infect mice. Egg laying was monitored until day 7 p.i. It was observed that L3 293 
treated with edelfosine at 20-40 µM for 24 hours were unable to develop patency in 294 
mice because no-eggs were found in faeces of mice challenged with these larvae. 295 
Similarly, mice challenged with ivermectin-treated-L3 (Fig. 3). In contrast, animals 296 
treated with 1-10 µM developed patent infections but with a significant reduction in 297 
eggs per gram of faeces compared to infected controls (Fig. 3).298 
299 
3.6. Edelfosine in vivo activity in mice infected by S. venezuelensis300 
301 
CD1 mice were subcutaneously infected with 3000 S. venezuelensis larvae and 302 
then orally treated with edelfosine during five consecutive days in order to reach a 303 
therapeutic level of the drug after day 5 p.i. when larvae are finishing their migration 304 
and reaching maturity and first eggs appear in faeces. In the first experiment, a 305 
significant reduction of 47% was observed in parthenogenetic females recovered from 306 
small intestines of edelfosine-treated mice on day 7 p.i (350 ± 162 females) compared 307 
to infected controls (661 ± 259 females). A non-significant reduction in faecal egg 308 
counts (23 %) was observed on day 7 p.i (65577 ± 10402 EPG cf 85171 ± 41012 EPG; 309 
Fig. 4). In the second experiment to assess the efficacy on egg laying curves significant 310 
reductions of faecal egg counts were observed from day 9 to the end of the 311 
experiment (Fig. 5). 312 
313 
3.7. Assessment of apoptosis-like cell death by TUNEL assay  314 
The above results suggested that edelfosine induced killing of S. venezuelensis larvae. 315 
S. venezuelensis L3 larvae treated with 100 µM edelfosine for 72h were analysed for the 316 
induction of a putative apoptosis-like death by using the terminal deoxynucleotidyl 317 
transferase-mediated dUTP nick-end labelling (TUNEL) technique for detecting DNA 318 
fragmentation. Labelling of the 3′-OH ends of fragmented DNA with fluorescein-12- 319 
dUTP allowed visualization of apoptotic-like cells. Cells were permeabilized and 320 
stained with propidium iodide to visualize nuclei from both non-apoptotic and apoptotic 321 
cells in red, whereas TUNEL-positive cells, representing apoptotic cells, were stained in 322 
green. As shown in Fig. 6, a potent and extensive DNA fragmentation along the 323 
whole parasite was found, suggesting an apoptosis-like response in edelfosine-treated 324 
S. venezuelensis L3 larvae along the whole parasite.  325 
326 
4. Discussion327 
The present study provides the first insights into the chemotherapeutic potential of the 328 
edelfosine against the infection caused by the nematode S. venezuelensis in a murine 329 
model. The study employed a series of in vitro and in vivo experiments and also 330 
reveals an approximation to its mode of action using the TUNEL assay. The APLs are a 331 
group of molecules, which have shown a wide variety of biological functions and have 332 
also been assayed against several protozoa, nematodes and trematodes. There are not 333 
previous reports in the literature concerning the use APLs for the treatment of 334 
strongyloidiasis. Here edelfosine showed the more potent activity against larval S. 335 
venezuelensis in vitro than other APLs ranked as follows: edelfosine > miltefosine > 336 
perifosine. It was also demonstrated that the efficacy of edelfosine in S. venezuelensis 337 
infections in mice. Although its activity is not as effective as ivermectin, currently the 338 
primary drug for treatment of strongyloidiasis, our data suggests that oral treatment 339 
with edelfosine decreases significantly both the number of eggs per gram of faeces and 340 
the number of parasitic female worms in the gut of mice. This efficacy is in 341 
concordance with the schistomicidal activity against adults in vitro and in vivo and 342 
the reduction of tissue egg burden in mice treated orally with edelfosine (Yepes et al. 343 
2014). Moreover, a combination of edelfosine and praziquantel has demonstrated 344 
efficacy against schistosomula (Yepes et al. 2015). There is also evidence that 345 
edelfosine is active against embryos and eggs of Caenorhabditis elegans (Sanchez- 346 
Blanco et al. 2014). Furthermore, edelfosine is active against protozoa such as 347 
Leishmania major, L panamensis and L. braziliensis in infected macrophage in culture 348 
and in experimental infections in mice and hamsters (Varela et al. 2012). In 349 
S. venezuelensis infection, faecal eggs are found on day 5 p.i peaking on days 7-8 p.i 350 
and are cleared by 20 days p.i allowing to assess new drugs in a short time. Moreover is 351 
a synchronous infection permitting to study the effect on each parasitic phase. 352 
Edelfosine needs around 5 days to reach therapeutical concentration (Yepes et al. 353 
2014) thus its administration had to start at the time of infection to reach therapeutical 354 
concentrations at the time when most of the parasites are adults. Further studies should 355 
be carried out to address the use of edelfosine as an alternative or preventive treatment. 356 
In addition, induction of apoptosis-like cell death was observed in 357 
S. venezuelensis larvae following edelfosine treatment as assessed by TUNEL assay. 358 
The data reported here indicate that edelfosine induces DNA strand breaks in 359 
S. venezuelensis larvae, likely through an apoptosis-like cell death mechanism 360 
involved in the antiparasitic action of edelfosine. This suggests a major role of an 361 
apoptosis-like response in the cell death mechanism but additional putative mechanisms 362 
cannot be ruled out. This is in agreement with the ability of edelfosine to promote 363 
apoptosis or apoptosis-like cell death in a number of distinct cell targets, including 364 
cancer cells (Gajate and Mollinedo 2007) as well as Leishmania and Schistosoma 365 
parasites (Varela et al. 2012, Yepes et al. 2015) as visualized by TUNEL assays. It has 366 
also been observed that apoptosis could be an effective mechanism using nitric oxide 367 
donors in S. venezuelensis larvae and in vitro cultures of adults (Ruano et al. 2012). 368 
Activated macrophages and treatment with edelfosine could be synergistic against this 369 
nematode. 370 
Since its introduction for the treatment of strongyloidiasis, ivermectin was 371 
considered the drug of choice for this purpose together with albendazole, mebendazole 372 
and thiabendazole. All these drugs have broad-spectrum anthelmintic effect and have 373 
been used widely against human and veterinary parasites. Benzimidazole and 374 
ivermectin resistant-nematode strains have also been reported in grazing livestock 375 
(von Samson- Himmelstjerna 2012, Shalaby 2013) and the issue of decreased 376 
susceptibility in human nematodes or the possibility of resistance is also increasing 377 
(Geerts and Gryseels 2000, Osei-Atweneboana et al. 2011, Vercruysse et al. 2011). 378 
Moreover, ivermectin treatment failure has also been observed in coinfected patients 379 
with S. stercoralis and human T- lymphotropic virus-1 (HTLV-1) and also adverse 380 
events linked to sensitive human genotypes (Carvalho and Da Fonseca Porto 2004, 381 
Bourguinat et al. 2010). These situations make the identification of alternative 382 
chemotherapies a high priority issue. 383 
Our results indicate that edelfosine significantly reduces worm recovery and egg laying 384 
in experimental infections and kills L3 in vitro through an apoptotic-like cell death 385 
mechanism. The proapoptotic activity of edelfosine as a putative mechanism opens the 386 
possibility to combination of drugs that could promote a synergistic action or minimize 387 
the possibility of drug resistance (Panic et al. 2014). In addition, edelfosine offers 388 
additional advantages as an antiparasitic drug, such as the activity against different 389 
tumoral cells (Mollinedo et al. 2010), and the anti-inflammatory activity shown by this 390 
APL together with its low toxicity profile (Mollinedo et al. 2009), could be of interest in 391 
treatment of strongyloidiasis patients coinfected with Leishmania or Schistosoma 392 
parasites (Yepes et al. 2014). 393 
In conclusion, strongyloidicidal activity of the alkylphospholipid edelfosine 394 
against S. venezuelensis was demonstrated using L3 cultures and a strongyloidiasis 395 
murine model, possibly through induction of apoptosis-like cell death. It was found 396 
significant reductions in egg burden, and it might thus warrant further investigation 397 
in other in order to establish the advantage as a therapeutical drug in soil-transmitted 398 
helminthic infections.399 
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Figure legends 414 
415 
Fig. 1. The chemical structure of the alkylphospholipids edelfosine, miltefosine and 416 
perifosine.417 
418 
Fig. 2. In vitro effects of edelfosine, miltefosine and perifosine on the viability of 419 
S. venezuelensis third stage larvae by the XTT assay (mean ± SD) cultured for 72 h. 420 
ANOVA: edelfosine F(7, 40) = 294.0, P < 0.001; miltefosine F(7, 40) = 99.3, P < 0.001; 421 
perifosine F(7, 40) = 85.6 P < 0.001 * Significant reduction compared to untreated control 422 
group post-hoc Tukey’s honest significance test P < 0.001 423 
424 
Fig. 3. Faecal egg production (mean ± SD) in mice infected with third stage larvae 425 
treated with increasing concentrations of edelfosine. ANOVA: edelfosine F(5, 29) = 92.1, 426 
P < 0.001; miltefosine F(5, 29) = 69.1, P < 0.001; perifosine F(5, 29) = 49.5 P < 0.001 * 427 
Significant reduction compared to untreated control group post-hoc Tukey’s honest 428 
significance test P < 0.05. 429 
430 
Fig. 4. Box-plots plus means (+) showing effects of the treatment with edelfosine and 431 
ivervectin in mice infected with 3000 S. venezuelensis L3 on day 7 post-infection in (A) 432 
parasitic females recovered from the intestine and (B) faecal egg count. ANOVA: 433 
parasitic females F(2, 12) = 17.5, P < 0.001; faecal egg count F(2, 12) = 16.7, P < 0.001. 434 
*Significant reduction compared to untreated control group post-hoc Tukey’s honest 435 
significance test P < 0.01. 436 
437 
438 
439 
Fig. 5. Faecal egg emission (mean ±SD) in mice infected with 3000 S. venezuelensis440 
and treated with edelfosine and ivermectin on days 5, 9, 11, 15, 17 and 19 post-441 
infection. ANOVA: day 9 p.i. F(2, 15) = 24.2, P < 0.001; day 11 p.i. F(2, 15) = 3.7, P = 442 
0.049; day 15 p.i. F(2, 15) = 19.8, P < 0.001; day 17 p.i. F(2, 15) = 16.6, P < 0.001; day 19 443 
p.i. F(2, 15) = 7.5, P = 0.005. * Significant reduction in edelfosine treated mice compared 444 
to untreated control group post-hoc Tukey’s honest significance test P < 0.05. 445 
446 
Figure 6. Assessing the apoptotic effect of edelfosine using the TUNEL assay. S. 447 
venezuelensis-L3 were treated with 100 µM edelfosine for 72 h, and then analysed by 448 
confocal microscopy for propidium iodide staining (PI), visualizing in red all the 449 
parasite cells (A), TUNEL assay, staining in green the cells with disrupted DNA, and 450 
differential interference contrast (DIC). Merged images of PI and TUNEL panels show 451 
the apoptotic nuclei in yellow. Data shown are representative of four experiments 452 
performed.453 
454 
Appendix A. Supplementary data 455 
Videos. The effect of alkylphospholipids edelfosine (videos S1-S3), miltefosine (videos 456 
S4-S6) and perifosine (videos S7-S9) on S. venezuelensis larvae was scored as change 457 
in the pattern of motility in videos. Mortality was attributed as any movement detected 458 
during 2 min of observation under the microscope (magnifications 4x) [1], at 24, 48 and 459 
72 h. Untreated S. venezuelensis larvae and ivermectin-treated larvae are also shown in 460 
each supplementary video. 461 
462 
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Table 1. Cytotoxic effects of alkylphospholipids edelfosine, miltefosine and perifosine on 
mouse-derived macrophages cell line J774.2 using the XTT assay (mean ±standard 
deviation).  
Concentration 
(µM) 
Edelfosine 
(OD) 
Miltefosine 
(OD) 
Perifosine 
(OD) 
Ivermectin 
(OD) 
Untreated 1.699 ± 0.013 1.635± 0.023 1.681± 0.031 1.639± 0.025 
1 1.551 ± 0.010 1.578 ± 0.068 1.575 ± 0.081 0.844 ± 0.038*
5 1.540 ± 0.022 1.557 ± 0.025 1.542 ± 0.023 0.747 ± 0.039*
10 1.474 ± 0.097 1.098 ± 0.338* 1.320 ± 0.225 0.662 ± 0.058*
40 0.930 ± 0.060* 0.765 ± 0.086* 0.922 ± 0.027* 0.575 ± 0.075*
80 0.792 ± 0.074* 0.694 ± 0.021* 0.864 ± 0.200 * 0.324 ± 0.002*
100 0.611  ± 0.021*
F
0.490 *± 0.053
F  = 29.3 
0.419 *± 0.035
F  = 36.8 
0.282 *± 0.047
F  = 65.4 ANOVA (5, 28) = 162.6 
P < 0.001
(5, 28)
P < 0.001
(5, 28)
P < 0.001
(5, 28)
P < 0.001
OD: Optical density at 492 nm. * Significant toxicity compared to untreated control group 
post­hoc Tukey’s honest significance test P < 0.001.
